XML 25 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Net revenues
 9 Months Ended
Sep. 29, 2019
Revenue from Contract with Customer [Abstract]  
Net revenues Net revenuesThe Company primarily generates revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with the Company’s customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when the Company’s products are shipped from the manufacturing or distribution facility. For the Company’s Original Equipment and Development Services ("OEM") segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and the Company has an enforceable right to payment to the extent that performance has been completed. The Company markets and sells products through its direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers such as pharmacies, which comprised 88%, 10% and 2% of consolidated net revenues, respectively, for the nine months ended September 29, 2019. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.
The following table disaggregates revenue by global product category for the three and nine months ended September 29, 2019 and September 30, 2018.
Three Months EndedNine Months Ended
September 29, 2019September 30, 2018September 29, 2019September 30, 2018
(Dollars in thousands)
Vascular access$148,681  $142,079  $446,225  $426,256  
Anesthesia87,123  87,531  253,098  261,764  
Interventional106,883  99,975  314,852  288,306  
Surgical92,621  89,908  274,911  266,046  
Interventional urology73,629  48,995  201,312  138,969  
OEM55,444  54,838  166,110  153,286  
Other (1)
83,938  86,346  257,902  272,141  
Net revenues (2)
$648,319  $609,672  $1,914,410  $1,806,768  
(1) Revenues in the "Other" category in the table above include revenues generated from sales of the Company’s respiratory and urology products (other than interventional urology products). For the three and nine months ended September 29, 2019, the Company reclassified its cardiac products from "Other" to "Interventional". The comparative prior year period has been restated to conform to the current period presentation.
(2) The product categories listed above are presented on a global basis; in contrast, each of the Company’s reportable segments other than the OEM reportable segment are defined exclusively based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the Company’s geographically based reportable segments include net revenues from each of the non-OEM product categories listed above.